OtherClinical Investigations (Human)
Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study
Wenjia Zhu, Yuejuan Cheng, Xuezhu Wang, Shaobo Yao, Ru Jia, Jianming Xu, Chunmei Bai, Hong Zhao and Li Huo
Journal of Nuclear Medicine November 2019, jnumed.119.235093; DOI: https://doi.org/10.2967/jnumed.119.235093
Wenjia Zhu
1 Peking Union Medical College Hospital, China;
Yuejuan Cheng
1 Peking Union Medical College Hospital, China;
Xuezhu Wang
1 Peking Union Medical College Hospital, China;
Shaobo Yao
2 Tianjin Medical University General Hospital, China;
Ru Jia
3 The fifthMedical Center, General Hospital of PLA, China;
Jianming Xu
4 The fifth Medical Center, General Hospital of PLA, China;
Chunmei Bai
1 Peking Union Medical College Hospital, China;
Hong Zhao
5 Chinese Academy of Medical Sciences and Peking Union Medical College, China;
Li Huo
6 Peking Union Medical College hospital, China
Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 10
October 1, 2024
Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study
Wenjia Zhu, Yuejuan Cheng, Xuezhu Wang, Shaobo Yao, Ru Jia, Jianming Xu, Chunmei Bai, Hong Zhao, Li Huo
Journal of Nuclear Medicine Nov 2019, jnumed.119.235093; DOI: 10.2967/jnumed.119.235093
Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study
Wenjia Zhu, Yuejuan Cheng, Xuezhu Wang, Shaobo Yao, Ru Jia, Jianming Xu, Chunmei Bai, Hong Zhao, Li Huo
Journal of Nuclear Medicine Nov 2019, jnumed.119.235093; DOI: 10.2967/jnumed.119.235093
Jump to section
Related Articles
Cited By...
- SSTR Antagonists as Theranostic Option in Merkel Cell Carcinoma
- 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
- Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study
- The Emergence of Somatostatin Antagonist-Based Theranostics: Paving the Road Toward Another Success?
- 18F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors
- A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors